glp-1 drug The Revolution: From Diabetes and Obesity to Alzheimer's and PCOS Are Pills the Next Big

Endocr J (2003) 50:1136

NICE guidance (CG189) recommends considering pharmacotherapy only after dietary, exercise, and behavioural approaches have been started and evaluated

Recent Findings The results of multiple randomized clinical trials demonstrate that, among patients with type 2 diabetes, GLP1RAs reduce body weight and improve glucose levels and lipid metabolism

"Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression"

All these findings suggest the necessity of investigating the mechanisms of the protective effect of MSM, in order to develop strategies capable to increase performance in sport horses